74 related articles for article (PubMed ID: 14991862)
1. Inhibition of cell signaling by the combi-nitrosourea FD137 in the androgen independent DU145 prostate cancer cell line.
Qiu Q; Dudouit F; Banerjee R; McNamee JP; Jean-Claude BJ
Prostate; 2004 Apr; 59(1):13-21. PubMed ID: 14991862
[TBL] [Abstract][Full Text] [Related]
2. The combi-targeting concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properties.
Qiu Q; Dudouit F; Matheson SL; Brahimi F; Banerjee R; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):1-10. PubMed ID: 12497200
[TBL] [Abstract][Full Text] [Related]
3. "Combi-targeting" mitozolomide: conferring novel signaling inhibitory properties to an abandoned DNA alkylating agent in the treatment of advanced prostate cancer.
Fang Y; Qiu Q; Domarkas J; Larroque-Lombard AL; Rao S; Rachid Z; Gibbs BF; Gao X; Jean-Claude BJ
Prostate; 2012 Sep; 72(12):1273-85. PubMed ID: 22290742
[TBL] [Abstract][Full Text] [Related]
4. Differential responses of EGFR-/AGT-expressing cells to the "combi-triazene" SMA41.
Matheson SL; McNamee JP; Jean-Claude BJ
Cancer Chemother Pharmacol; 2003 Jan; 51(1):11-20. PubMed ID: 12497201
[TBL] [Abstract][Full Text] [Related]
5. The combi-targeting concept: in vitro and in vivo fragmentation of a stable combi-nitrosourea engineered to interact with the epidermal growth factor receptor while remaining DNA reactive.
Qiu Q; Domarkas J; Banerjee R; Merayo N; Brahimi F; McNamee JP; Gibbs BF; Jean-Claude BJ
Clin Cancer Res; 2007 Jan; 13(1):331-40. PubMed ID: 17200372
[TBL] [Abstract][Full Text] [Related]
6. Type II combi-molecules: design and binary targeting properties of the novel triazolinium-containing molecules JDD36 and JDE05.
Qiu Q; Domarkas J; Banerjee R; Katsoulas A; McNamee JP; Jean-Claude BJ
Anticancer Drugs; 2007 Feb; 18(2):171-7. PubMed ID: 17159603
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of epidermal growth factor receptor-mediated signaling by "Combi-triazene" BJ2000, a new probe for Combi-Targeting postulates.
Brahimi F; Matheson SL; Dudouit F; McNamee JP; Tari AM; Jean-Claude BJ
J Pharmacol Exp Ther; 2002 Oct; 303(1):238-46. PubMed ID: 12235257
[TBL] [Abstract][Full Text] [Related]
8. Transactivation of epidermal growth factor receptor after heparin-binding epidermal growth factor-like growth factor shedding in the migration of prostate cancer cells promoted by bombesin.
Madarame J; Higashiyama S; Kiyota H; Madachi A; Toki F; Shimomura T; Tani N; Oishi Y; Matsuura N
Prostate; 2003 Nov; 57(3):187-95. PubMed ID: 14518027
[TBL] [Abstract][Full Text] [Related]
9. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells.
Zi X; Grasso AW; Kung HJ; Agarwal R
Cancer Res; 1998 May; 58(9):1920-9. PubMed ID: 9581834
[TBL] [Abstract][Full Text] [Related]
10. The combi-targeting concept: dissection of the binary mechanism of action of the combi-triazene SMA41 in vitro and antitumor activity in vivo.
Matheson SL; McNamee JP; Wang T; Alaoui-Jamali MA; Tari AM; Jean-Claude BJ
J Pharmacol Exp Ther; 2004 Dec; 311(3):1163-70. PubMed ID: 15358812
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of heparin binding EGF (HB-EGF), amphiregulin, TGF alpha and epiregulin in androgen-independent prostate cancer cell lines.
Tørring N; Jørgensen PE; Sørensen BS; Nexø E
Anticancer Res; 2000; 20(1A):91-5. PubMed ID: 10769639
[TBL] [Abstract][Full Text] [Related]
12. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
13. Differential roles of ERK and Akt pathways in regulation of EGFR-mediated signaling and motility in prostate cancer cells.
Gan Y; Shi C; Inge L; Hibner M; Balducci J; Huang Y
Oncogene; 2010 Sep; 29(35):4947-58. PubMed ID: 20562913
[TBL] [Abstract][Full Text] [Related]
14. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer cells generated during intermittent androgen ablation acquire a growth advantage and exhibit changes in epidermal growth factor receptor expression.
Hobisch A; Fiechtl M; Sandahl-Sorensen B; Godoy-Tundidor S; Artner-Dworzak E; Ramoner R; Bartsch G; Culig Z
Prostate; 2004 Jun; 59(4):401-8. PubMed ID: 15065088
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation is involved in chemoresistance induced by EGF in prostate cancer cells.
Li Y; Chen HQ; Chen MF; Liu HZ; Dai YQ; Lv H; Bing Zu X; Qi L
Life Sci; 2009 Jun; 84(25-26):882-7. PubMed ID: 19356736
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.
Jia RP; Xu LW; Su Q; Zhao JH; Li WC; Wang F; Xu Z
Asian J Androl; 2008 Sep; 10(5):758-64. PubMed ID: 18645679
[TBL] [Abstract][Full Text] [Related]
18. Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines.
Chow L; Rezmann L; Imamura K; Wang L; Catt K; Tikellis C; Louis WJ; Frauman AG; Louis SN
Prostate; 2008 May; 68(6):651-60. PubMed ID: 18288685
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of epidermal growth factor receptor signaling by Saussurea involucrata, a rare traditional Chinese medicinal herb, in human hormone-resistant prostate cancer PC-3 cells.
Way TD; Lee JC; Kuo DH; Fan LL; Huang CH; Lin HY; Shieh PC; Kuo PT; Liao CF; Liu H; Kao JY
J Agric Food Chem; 2010 Mar; 58(6):3356-65. PubMed ID: 20166659
[TBL] [Abstract][Full Text] [Related]
20. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
